GammaDelta Therapeutics, a biotech company developing novel immunotherapies for cancer and other diseases, has appointed Michael Koslowski, MD, as chief medical officer. Michael has more than 20 years of experience in the discovery and development of immunotherapeutic drugs within academia, biotechnology and pharmaceutical companies. Most recently, he was EVP research & development and chief medical officer of Mission Therapeutics. Prior to Mission, he was VP clinical sciences & early development at Glenmark Pharmaceuticals and managed the translational medicine initiative at Boehringer Ingelheim across all therapeutics areas.
